Yuling Zhou Selected Research

Yuling Zhou Research Topics

Disease

11	Neoplasms (Cancer) 05/2024 - 01/2002
4	Adenocarcinoma of Lung 01/2022 - 01/2020
3	Hemorrhage 01/2023 - 01/2019
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2020
2	Infections 03/2024 - 10/2013
2	Lung Neoplasms (Lung Cancer) 10/2023 - 01/2023
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 12/2021
2	Blindness (Hysterical Blindness) 01/2023 - 01/2018
2	Inflammation (Inflammations) 01/2023 - 03/2016
2	Disease Progression 01/2022 - 01/2020
2	Fibrosis (Cirrhosis) 07/2021 - 06/2019
2	Adenocarcinoma 09/2020 - 06/2020
2	Chronic Hepatitis B 06/2019 - 01/2019
2	T-Cell Lymphoma (Lymphoma, T Cell) 05/2014 - 04/2012
2	Myocardial Infarction 05/2004 - 11/2003
1	Hepatitis 10/2023
1	Thrombosis (Thrombus) 01/2023
1	Pulmonary Embolism 01/2023
1	Choroidal Neovascularization 01/2023
1	Macular Degeneration (Age-Related Maculopathy) 01/2023
1	Nasopharyngeal Carcinoma 01/2023
1	Aortic Dissection 01/2023
1	Pathologic Constriction (Stenosis) 01/2023
1	Wounds and Injuries (Trauma) 01/2023
1	Squamous Cell Carcinoma of Head and Neck 10/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2022
1	Nasopharyngitis 01/2022
1	Gallstones (Gallstone) 01/2021
1	Cholelithiasis 01/2021
1	Chorea (Rheumatic Chorea) 12/2020
1	Cerebellar Ataxia (Dysmetria) 12/2020
1	Intestinal Pseudo-Obstruction (Intestinal Pseudoobstruction) 12/2020
1	Myasthenia Gravis 12/2020
1	Lambert-Eaton Myasthenic Syndrome (Lambert-Eaton Syndrome) 12/2020
1	Gallbladder Neoplasms (Gallbladder Cancer) 09/2020
1	Obstructive Jaundice (Cholestatic Jaundice) 09/2020
1	COVID-19 01/2020
1	Hepatitis B 06/2019
1	Rheumatoid Arthritis 04/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2019
1	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2018
1	Retinal Neovascularization 01/2018

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 05/2024 - 12/2020
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2022
2	Immune Checkpoint InhibitorsIBA 10/2023 - 10/2022
2	CytokinesIBA 10/2023 - 04/2012
2	CrizotinibIBA 01/2022 - 09/2020
2	Peptides (Polypeptides)IBA 10/2013 - 01/2002
1	Anti-Bacterial Agents (Antibiotics)IBA 03/2024
1	Bevacizumab (Avastin)FDA Link 01/2023
1	Rilpivirine (TMC-278)IBA 01/2023
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2023
1	Angiogenesis InhibitorsIBA 01/2023
1	Anti-HIV Agents (AIDS Drugs)IBA 01/2023
1	Adenosine Diphosphate (ADP)IBA 01/2023
1	fibrin fragment D (D-dimer)IBA 01/2023
1	Endothelial Growth FactorsIBA 01/2023
1	graphene oxideIBA 01/2023
1	IntegrinsIBA 01/2023
1	Gemcitabine FDA Link 10/2022
1	Cisplatin (Platino)FDA LinkGeneric 10/2022
1	toripalimabIBA 10/2022
1	Albumin-Bound Paclitaxel FDA Link 04/2022
1	Carboplatin (JM8)FDA LinkGeneric 04/2022
1	N-acetyltalosaminuronic acid (NAT)IBA 04/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	Gefitinib (Iressa)FDA Link 01/2022
1	Anaplastic Lymphoma KinaseIBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	LigandsIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Piwi-Interacting RNAIBA 12/2021
1	Adenosine (Adenocard)FDA LinkGeneric 07/2021
1	Matrix Metalloproteinases (MMPs)IBA 07/2021
1	CholesterolIBA 01/2021
1	AntibodiesIBA 12/2020
1	Retinaldehyde (Retinal)IBA 12/2020
1	Semaphorin-3AIBA 12/2020
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 09/2020
1	Capecitabine (Xeloda)FDA Link 09/2020
1	anlotinibIBA 06/2020
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2020
1	lorlatinibIBA 01/2020
1	pembrolizumabIBA 01/2020
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2020
1	130-nm albumin-bound paclitaxelIBA 01/2020
1	apatinibIBA 01/2020
1	Antiviral Agents (Antivirals)IBA 06/2019
1	AntioxidantsIBA 04/2019
1	Sweetening Agents (Sweeteners)IBA 04/2019
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2018

Therapy/Procedure

9	Therapeutics 03/2024 - 09/2015
4	Drug Therapy (Chemotherapy) 03/2024 - 01/2020
3	Radiotherapy 01/2023 - 09/2015
2	Neoadjuvant Therapy 10/2022 - 04/2022
1	Immunotherapy 01/2023
1	Quantum Dots (Quantum Dot) 01/2023
1	Adjuvant Chemotherapy 04/2022
1	Molecular Targeted Therapy 01/2022